Moteur de recherche d’entreprises européennes
Financement de l’UE (2 999 220 €) : Stop Adverse Fluid Events in Infusion : dispositifs de connexion de tube et d’évacuation de l’air à maillon faible pour un traitement IV plus sûr, plus précis et … Hor10/03/2021 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Stop Adverse Fluid Events in Infusion : dispositifs de connexion de tube et d’évacuation de l’air à maillon faible pour un traitement IV plus sûr, plus précis et plus rentable à l’hôpital et à domicile.
Intravenous (IV) therapy is the most performed invasive treatment with 3.8 bn disposables tubes used annually. This procedure is not safe, neither for healthcare personnel nor patients, with serious consequences such as accidental IV dislodgement and Vascular Air Embolism (VAE) generating additional healthcare costs of €43b every year. In addition, there is a growing trend to administer IV infusion at home presenting social and economic benefits to patients with chronic diseases, cancer and, being especially important, to the current aging European population. In views of the situation, there is an urgent need for IV therapy risk reduction by preventing dislodgement, VAE and spill of hazardous fluids/vapours, while simultaneously supporting the ‘bringing care home initiative’. In response, we have developed ReAL, a weak-link tube connection and air removal devices that will make IV therapy more accurate and safer for healthcare personnel and patients by i) preventing accidental dislodgement, and ii) removing harmful air bubbles in a closed system,. ReAL helps patients to receive a more accurate dose with faster recovery, while healthcare providers save money. Providing IV therapy at home has shown a 90% potential cost saving compared to corresponding care provided in the hospital. In this SAFE-Infusion project we aim to disrupt the IV tube market by maturing, testing, and launching the next- generation tube connection and air removal device. Within the first five years post project, we estimate total accident-related cost-savings of €3.3bn for healthcare (i.e., €28 for each €1 spent in ReAL), 57 tonnes of plastic waste saved, €114m in accumulated revenues and €44m in accumulated operating profit for the SAFE-Infusion industry partners together.
| Fundacio Privada Per A La Recerca i La Docencia Sant Joan de Deu | 358 128 € |
| Interlinked AB | 1 046 509 € |
| Parc Sanitari Sant Joan de Deu | 0,00 € |
| Remote Signals Ltd. | 198 493 € |
| Tessen Solutions Ltd. | 1 087 027 € |
| Unidade Local de Saude de Coimbra ΕΠΕ | 309 063 € |
https://cordis.europa.eu/project/id/971225
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Fundacio Privada Per A La Recerca i La Docencia Sant Joan de Deu - Financement de l’UE (2 999 220 €) : Stop Adverse Fluid Events in Infusion : dispositifs de connexion de tube et d’évacuation de l’air à maillon faible pour un traitement IV plus sûr, plus précis et …"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
